ETV6 is an inclusion criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain ETV6 status and acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open) [4].

ETV6 is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

ETV6 is an inclusion criterion in 3 clinical trials for congenital mesoblastic nephroma, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and congenital mesoblastic nephroma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 3 clinical trials for infantile fibrosarcoma, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and infantile fibrosarcoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 3 clinical trials for secondary acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

ETV6 is an inclusion criterion in 2 clinical trials for acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and acute leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

ETV6 is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ETV6 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 2 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ETV6 is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ETV6 is an inclusion criterion in 1 clinical trial for secretory breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and secretory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].